GlassScriptPhysician profile
Bryan J Krull
NPI 1649296682
$8,840.72
in general payments reported to CMS, 2019-2025
49 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $974 · 2021: $911 · 2022: $1,425 · 2023: $1,913 · 2024: $1,376 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,146 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.64 |
| Education | $339.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,026.07 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $860.03 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $770.20 | 2020-2025 | Jynarque |
| Amgen INC. | $584.98 | 2019-2025 | Krystexxa, Tavneos |
| Ardelyx, INC. | $541.00 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $415.09 | 2019-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $380.00 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $369.11 | 2019-2023 | Veltassa |
| Horizon Therapeutics Plc | $334.01 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $318.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $316.97 | 2020-2025 | |
| Calliditas Therapeutics US INC. | $313.41 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $236.49 | 2022-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $232.58 | 2019 | |
| Fresenius USA Marketing, INC. | $211.76 | 2019-2024 | Velphoro |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Krull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.